Clinical Trial: Methods and DesignRationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF)
Section snippets
Overview
LAPTOP-HF is a prospective, multicenter, randomized, controlled clinical trial in ambulatory patients with advanced HF that will evaluate the safety and clinical effectiveness of implanted LAP monitoring systems linked with a physician-directed patient self-management therapeutic strategy. The trial will enroll up to 730 patients with NYHA functional class III symptoms and either a hospitalization for HF during the previous 12 months or an elevated B-type natriuretic peptide (BNP) level of ≥400
LAPTOP Monitoring Systems
Two implantable LAP monitoring systems (Fig. 1) manufactured by St Jude Medical (Sylmar, California) will be used depending on clinical indications and the implanter’s discretion. A stand-alone system includes a HeartPOD implantable sensor lead (ISL) that measures the LAP waveform, core temperature, and the intracardiac electrogram (IEGM). The ISL is coupled to an implantable communications module (ICM), which communicates the measured signals to an external radiofrequency (RF) source/reader.
Subjects and Randomization
Subjects meeting the inclusion/exclusion criteria (Table 1) and giving informed consent will be randomized in a 1:1 ratio into the treatment and control groups. The trial will enroll up to 730 patients at up to 75 centers. Randomization will be stratified 3 ways as indicated in Table 2.
Stratum 1 includes subjects with a baseline LVEF ≤35% and no new indication for CRT per American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Rhythm Society/European Society of Cardiology
Study Procedures and Follow-up
An experienced proctor will be present at each new implanting physician's initial procedures to assure adequate training and compliance with the protocol until both the sponsor and physician consider that it is no longer necessary. To provide training in the use of the Web-based software and achieve compliance with the protocol treatment group prescribing guidelines, Web-based LAP system technical assistance rounds are done with each site. Technical issues with patients from both treatment and
Study End Points
The primary safety end point is freedom from study-related major adverse cardiovascular and neurologic events (MACNE) in the treatment group at 12 months. The primary effectiveness end point is the reduction in the relative risk of HF hospitalization, including ADHF and complications of HF treatment such as hypotension and acute renal failure.
Secondary end points include (1) noninferiority analysis of the relative risk of all-cause MACNE (safety) and (2) days alive and out of hospital for HF
Power Calculation and Statistical Analyses
The sample size was calculated under the following assumptions: (1) the event rate for HF hospitalization in the control group is 0.6 per patient per year, (2) relative risk reduction of HF-related hospitalizations in the Treatment group over the control group is 25%, and (3) withdrawal rate is 25% at 12 months. For 80% power at a 5% significance level, 624 events are required. The number of patients needed to enroll is a maximum of 730.
The power calculation for the primary safety end point
Monitoring
The Steering Committee in collaboration with the sponsor developed the study protocol and is responsible for monitoring its implementation. The independent Clinical Events Committee (CEC) adjudicates the cardiac and noncardiac events that qualify as an end point. The CEC includes physicians with expertise in clinical trials, cardiovascular diseases, and statistics. Source documentation for events considered for the primary effectiveness end point is redacted to blind for study group assignment.
Discussion
Implantable hemodynamic monitoring has been developed for outpatient HF management with the goal of improving outcomes by reducing episodes of decompensation, providing adjunctive information to patients that could promote adherence to diet and lifestyle management and assist in the titration of standard medical therapy to optimally tolerated dosages. Previous studies have suggested that management of ambulatory hemodynamics may improve outcomes in patients with advanced chronic HF.10, 19, 20,
Disclosures
This trial is sponsored by St Jude Medical. Drs Mathew S. Maurer, Phil Adamson, Marc Klapholz, Leslie Saxon, Jagmeet P. Singh, and William T. Abraham are on the LAPTOP-HF Steering Committee and receive financial compensation for this activity. Dr Michael R. Gold is a consultant and does clinical trials for St Jude Medical, Boston Scientific, and Medtronic and is on the LAPTOP-HF Steering Committee. Dr Richard Troughton is on the LAPTOP Steering Committee and receives grant funding from St Jude
References (24)
- et al.
Relationships between emerging measures of heart failure processes of care and clinical outcomes
Am Heart J
(2010) - et al.
Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)
Am Heart J
(2005) - et al.
Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study
J Am Coll Cardiol
(2008) - et al.
Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial
Lancet
(2011) - et al.
Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial
J Card Fail
(2008) - et al.
CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system
J Card Fail
(2011) - et al.
Noninvasive calibration of cardiac pressure transducers in patients with heart failure: an aid to implantable hemodynamic monitoring and therapeutic guidance
J Card Fail
(2006) - et al.
ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons
J Am Coll Cardiol
(2008) - et al.
ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary
Heart Rhythm
(2008) - et al.
2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation
J Am Coll Cardiol
(2009)
Comparison of a radiofrequency-based wireless pressure sensor to Swan-Ganz catheter and echocardiography for ambulatory assessment of pulmonary artery pressure in heart failure
J Am Coll Cardiol
Heart disease and stroke statistics—2010 update: a report from the American Heart Association
Circulation
Cited by (60)
Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction
2024, Journal of the American College of CardiologyRemote Monitoring Devices and Heart Failure
2024, Heart Failure ClinicsBenefits of remote hemodynamic monitoring in heart failure
2023, Trends in Cardiovascular MedicineImplantable devices for heart failure monitoring
2021, Progress in Cardiovascular DiseasesCitation Excerpt :This was followed by LAPTOP-HF trial utilizing the HeartPOD system in NYHA class III HF patients with a HFH in the prior 12 months or an elevated BNP regardless of ejection fraction. This study was a prospective, multicenter unblinded randomized trial utilizing individualized physician-directed, patient self-managed, HF therapy based on the LAP measurement measured twice daily.64,65 Although the trial was stopped before achieving target patient enrollment due to perceived procedure related complications, the trial did meet the safety end point of freedom from procedure or device related cardiac or neurologic adverse events.
MONITORIA: The start of a new era of ambulatory heart failure monitoring? Part I – Theoretical Rationale
2021, Revista Portuguesa de CardiologiaCitation Excerpt :Hence, continuous monitoring of LAP may also provide an excellent method of HF monitoring. There is an ongoing trial (LAP-Top-HF study) designed to assess the role of implantable LAP monitoring in association with guiding therapeutics in HF.51 Nevertheless, we aim to accurately monitor LAP, as well as RAP, in a non-invasive way, using the MONITORIA device.
See page 487 for disclosure information.